Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study

Dandan Mao, Huanyi Cao, Mai Shi, Chi Chiu Wang, Joseph Kwong, Joshua Jing Xi, Yong Hou, Xing Ming, Heung Man Lee, Xiao Yu Tian, Chun Kwok Wong, Elaine Chow, Alice Pik Shan Kong, Vivian Wai Yan Lui, Paul Kay Sheung Chan, Juliana Chung Ngor Chan

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China
Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China

ABSTRACT

Background: Type 2 diabetes (T2D) increases the risk of many types of cancer. Dysregulation of proteasome-related protein degradation leads to tumorigenesis, while Exendin-4, a glucagon-like peptide 1 receptor (GLP-1R) agonist, possesses anti-cancer effects.

Methods: We explored the co-expression of proteasome alpha 2 subunit (PSMA2) and GLP-1R in the Cancer Genome Atlas (TCGA) database and human cervical cancer specimens, supplemented by in vivo and in vitro studies using multiple cervical cancer cell lines.

Findings: PSMA2 expression was increased in 12 cancer types in TCGA database and cervical cancer specimens from patients with T2D (T2D vs non-T2D: 3.22 (95% confidence interval CI: 1.38, 5.05) vs 1.00 (0.66, 1.34) fold change, P = 0.01). psma2-shRNA decreased cell proliferation in vitro, and tumour volume and Ki67 expression in vivo. Exendin-4 decreased psma2 expression, tumour volume and Ki67 expression in vivo. There was no change in GLP-1R expression in 12 cancer types in TCGA database. However, GLP-1R expression (T2D vs non-T2D: 5.49 (3.0, 8.1) vs 1.00 (0.5, 1.5) fold change, P < 0.001) was increased and positively correlated with PSMA2 expression in T2D-related (r = 0.68) but not in non-T2D-related cervical cancer specimens. This correlation was corroborated by in vitro experiments where silencing glp-1r decreased psma2 expression. Exendin-4 attenuated phospho-p65 and -IκB expression in the NF-κB pathway.

Interpretation: PSMA2 and GLP-1R expression in T2D-related cervical cancer specimens was increased and positively correlated, suggesting hyperglycaemia might promote cancer growth by increasing PSMA2 expression which could be attenuated by Exendin-4.

Funding: This project was supported by Postdoctoral Fellowship Scheme, Direct Grant, Diabetes Research and Education Fund from the Chinese University of Hong Kong (CUHK)

© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Diabetes increases the risk of many cancer types and cancer-related death, particularly in liver, pancreas, colorectal cancer, and lung cancer [1]. In patients with type 2 diabetes (T2D), a 1% increase in HbA1c is associated with 1.18-fold increased risk of cancer [2,3].

* Corresponding author at: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, 30-32 Ngan Shing St, Shatin, N.T., Hong Kong SAR, China.
E-mail address: jchan@cuhk.edu.hk (J.C.N. Chan).
**Research in context**

**Evidence before this study**

Diabetes increases the risk of cancer and cancer-related death. Inflammation is common in cancer and diabetes, especially for virus infection-induced cancer, e.g., human papillomavirus (HPV)-16 and -18 related cervical cancer. The ubiquitin-proteasome system is responsible for protein homeostasis, which is disrupted in carcinogenesis. Exendin-4 has been shown to attenuate cancer growth in prostate, pancreatic, and breast cancer. We previously reported the attenuating effect of Exendin-4 on tumour growth in db/db mice induced by mouse epithelial cervical cancer cells (CUP-1, The Chinese University of human Papilloma virus-1).

**Added value of this study**

We demonstrated the proto-oncogenic role of PSMA2 in cervical cancer specimens from patients with T2D with corroborative evidence from cellular and animal models. Importantly, we discovered the increased co-expression of GLP-1R and PSMA2 in human and experimental models of cervical cancer, promoted by hyperglycemia but attenuated by Exendin-4.

**Implications of all of the available evidence**

Since proteasome inhibitors and GLP-1 mimetics are in clinical use, our data have strong translational potential. Given the increased co-expression of GLP-1R and PSMA2 in cervical cancer and the proto-oncogenic role of PSMA2, GLP-1R agonist might have the potential to treat cancer especially in patients with T2D.

Sexual activity-related cancer, including cervical, oropharyngeal, and anal cancers due to infection of human papillomavirus (HPV)-16 and -18 [4], are not uncommon in T2D. Inflammation, often associated with low-grade chronic infection, plays an important role in carcinogenesis. As such, the co-existence of diabetes and virus infection may create an inflammatory microenvironment to promote cancer cell growth [2,5]. Moreover, T2D is associated with poor survival in patients with cervical cancer, making T2D an important prognostic factor for cervical cancer [6]. Genetic mutations, chemical irritation, irradiation, toxins, bacteria, and virus infections are amongst the common causes of tumorigenesis [7,8]. Cancer is characterized by perturbation of cell growth and proliferation. The uncontrolled cell proliferation is supported by high protein turnover in cancer cells. The ubiquitin-proteasome system is essential for the maintenance of cellular protein homeostasis, i.e. the balance between normal protein synthesis and protein degradation [9]. An abnormal protein is first tagged by ubiquitin for its transfer to the cylinder-like structure of the proteasome complex with alpha and beta subunits for degradation into small peptides [10]. Increased proteasome expression or activity may contribute to carcinogenesis by promoting robust protein turnover [11]. Inhibition of the proteasome results in cell-cycle arrest and apoptosis, and is a target for anticancer therapy [12]. Recently, a proteasome gene, namely PSMA2, has been identified to promote breast cancer cell growth, indicative of its potential proto-oncogenic role in cancer [13]. A single nucleotide polymorphism (SNPs) c.328C>G, contributing to missense protein-coding in PSMA2, has been implicated in human breast and colorectal cancer [14,15].

In clinical practice, proteasome inhibitors, such as bortezomib and carfilzomib, are antitumor drugs approved for the treatment of multiple myeloma and lymphoma [16]. The inhibitor-κB (IκB)-nuclear factor-κB (NF-κB) pathway promotes inflammation which can lead to abnormal cell growth. Increased expression of proteasome can degrade IκB and release NF-κB with nuclear translocation to activate transcription of the inflammatory cytokines and cell signals. By blocking IκB degradation, proteasome inhibitors can prevent nuclear translocation of NF-κB and inhibit tumour growth [7].

GLP-1 is an incretin hormone released from the L cells in the lower intestine. It can augment insulin release during meal-time and suppress glucagon production [17]. Glucagon-like peptide 1 mimetics include GLP-1 receptor agonist, such as Exendin-4 which binds with GLP-1R, and dipeptidyl peptidase 4 (DPP-4) inhibitor which inhibits the degradation of GLP-1. These new classes of blood glucose-lowering drugs carry a low risk of hypoglycaemia with weight-neutral or weight-reducing effects [18,19].

There are emerging reports on the anti-cancer effects of GLP-1 mimetics although the mechanisms require further elucidation. Exendin-4 has been shown to attenuate the proliferation of human prostate cancer cells through inhibition of extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) [20]. In patients with prostate cancer, Exendin-4 enhanced the responsiveness to chemotherapy and reduced cancer growth by activating the phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR (the mammalian target of rapamycin) pathways [21]. In human pancreatic and breast cancer cell lines, GLP-1R agonist, liraglutide, attenuated cancer growth by inhibiting cellular proliferation and inducing apoptosis through inhibition of the NF-κB pathway [22,23]. In a meta-analysis of randomized controlled trials (RCTs) involving 63,594 patients with T2D, subgroup analyses indicated that treatment with albiglutide, a GLP-1 agonist, was associated with 24% (95% confidence interval (CI) 0.60-0.97) reduction of all-site cancer compared with the placebo group. However, the number of cancer cases was only 91 in the treatment group and 119 in the placebo group [24].

In experimental studies, GLP-1 has been shown to exert anti-inflammatory effects in multiple organs, including the heart, brain, kidney, liver, pancreas, skin, and testis [25]. This effect was in part mediated by suppressing the immune system such as macrophages, dendritic cells, and mast cells with reduced release of pro-inflammatory cytokines (e.g., interleukin (IL)-1β, IL-6, IL-12), nitric oxide (NO), and tumour necrosis factor (TNF)-α [26]. In this light, our group has reported the ex vivo inhibitory effects of Exendin-4 on the release of cytokines from peripheral blood mononuclear cells extracted from patients with T2D [27]. Using the Hong Kong Diabetes Register established since 1995, our group was amongst the first to report the high incidence of cancer in Chinese patients with T2D, which was closely associated with hyperglycemia [28,29]. These epidemiological studies have motivated our group to develop the CUP-1 epithelial cancer cell line to explore the mechanisms of this diabetes-cancer link. The CUP-1 is an immortal mouse epithelial cancer cell line generated from the kidney of embryonic C57BL/6J mice with the insertion of the HPV-16 E7 oncogene [30]. We established a diabetes/cancer model by subcutaneous inoculation of CUP-1 cancer cells in the diabetic db/db mice, followed by tumour growth to a maximum volume by day 14. Compared with vehicle, Exendin-4 attenuated the tumour growth [31] although the underlying mechanism remains unknown.

Both cancer and T2D are characterized by excessive protein turnover. Given the importance of proteasome in protein homeostasis, we interrogated TCGA database and noted increased expression of PSMA2 in 12 cancer types based on human samples, including cervical cancer. Supported by these clinical findings, we explored the effect of high glucose on PSMA2 expression in cervical cancer including human, in vivo, and in vitro systems. To further explore the anti-tumour effects of Exendin-4 reported in our previous experiment [31], we examined the expression of GLP-1R and the effect of Exendin-4 on psma2 expression and tumour growth and associated changes in the NF-κB pathway using cellular, animal and human samples.
Firstly, we hypothesize that PSMA2 expression was increased in cervical cancer from patients with T2D. Secondly, PSMA2-O/E and -shRNA increased and decreased cell proliferation under high glucose condition and tumour volume in db/db mice, respectively. Thirdly, high glucose increased GLP-1R expression in vitro and Exendin-4 reduced PSMA2 expression, decreased cell proliferation, and attenuated tumour volume. Lastly, GLP-1R expression was increased in cervical cancer specimens from patients with T2D.

We used complementary human specimens, in vivo, and in vitro models to test these hypotheses. We first examined PSMA2 expression in cervical cancer specimens from patients with T2D, followed by human and mouse cervical cancer cell lines. Secondly, we generated stable cell lines with psma2-O/E or -shRNA transfection in CUP-1 cells to explore the role of psma2 in cell proliferation and tumour growth. Thirdly, we examined the effect of Exendin-4 on psma2 expression, cell proliferation, and tumour growth. Fourthly, we examined GLP-1R expression and its correlation with PSMA2 expression in cervical cancer specimen from patients with T2D, followed by confirmation from cervical cancer cell lines. Lastly, we explored the effects of high glucose and Exendin-4 on the NF-κB pathway, including phospho-p65 and phospho-IκB levels.

2. Methods

2.1. Pan-cancer expression of PSMA2 and GLP-1R

TCGA database has comprehensive cancer genomic profiles, including transcriptomic data of over 30 human tumours [32]. Our bioinformaticist (MS) extracted publicly available mRNA expression profiles of PSMA2 and GLP-1R generated from RNA-sequencing experiments, and analysed their differences using Gene Expression Profiling Interactive Analysis 2 [33]. We examined 13 types of cancer including invasive breast carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), lymphoid neoplasm diffuse large B-cell lymphoma (DLBCL), oesophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), and thymoma (THYM). For each type of cancer, the gene expression was matched with that in normal samples in the Genotype-Tissue Expression (GTEX) database [34].

2.2. Cell lines and treatment

We used cancer cell lines including human breast cancer cell line MCF-7 (RRID: CVCL_0031), and non-cancerous cell lines including mouse fibroblastic cell line 1929 (RRID: CVCL_0462) and human embryonic kidney cell line 293 (RRID: CVCL_0045) to conduct a series of experiments. These cell lines were cultured in DMEM medium (Cat. 11885076, Invitrogen, USA) with 10% FBS, and 1% Antibiotic-Antimycotic. These cell lines included three human cervical cancer cell lines SiHa (RRID: CVCL_0032), HeLa (RRID: CVCL_0030), and C33A (RRID: CVCL_1094), which were cultured in MEM medium (Cat. 12571071, Invitrogen, USA) with 10% FBS, and 1% Antibiotic-Antimycotic. These cell lines have been validated by Department of Anatomical and Cellular Pathology core laboratory at the CUHK using DNA fingerprinting.

Our group established CUP-1 by incorporating HPV-16 E7 and activated Ej-ras oncogene into baby mouse kidney epithelial cells from C57BL/KSJ mice, which shares the same genetic background of db/db mice. We immortalized the cell line with stable expression of HPV-16 E7 oncogene, which was inoculated in db/db mice for tumour development [30,31]. CUP-1 cells were cultured in DMEM medium (Cat. 11885076, Invitrogen, USA) with 10% FBS, and 1% Antibiotic-Antimycotic.

The above cell lines underwent overnight serum starvation in medium with normal glucose and low FBS (1%). The culture medium was replaced with fresh medium with low (2.8mmol/L), normal (5.5 mmol/L) or high glucose (25 mmol/L) for 48h for molecular analysis. CUP-1 cells were treated with Exendin-4 (Cat. E7144, Sigma-Aldrich, US) at concentrations of 0, 5, 20, and 50 nmol/L for 6, 24, and 48 h. Cells for in vitro studies were passaged from one relevant cell lines in the same condition with highly homogenous phenotypes. All in vitro experiments were repeated at least twice with at least 3 samples in each experiment, hence results of 6 samples were analysed and presented.

2.3. Human tissue

A case-control study were conducted to compare the RNA and protein differences in PSMA2 and GLP-1R expression in cervical cancer specimens from patients with or without T2D. All specimens were obtained during radical hysterectomy performed at the Prince of Wales Hospital (PWH), the teaching hospital of the CUHK, between January 2016 and July 2019. We retrieved frozen tissue and histological samples of age-matched patients with or without T2D. Frozen samples were used for RNA expression analysis and cut into 3-mm sections for microdissection using a fine surgical blade to isolate tumour-specific cells under an inverted microscope.

The medical records of these patients were reviewed using the territory-wide electronic medical system shared by all publicly-funded hospitals and clinics. Diabetes was defined based on physician-diagnosed T2D and/or prescription of glucose-lowering drugs and/or abnormal laboratory values as defined by the American Diabetes Association guidelines: HbA1c > 6.5%, or fasting plasma glucose ≥ 7.0 mmol/L, or 2-h plasma glucose ≥ 11.1 mmol/L during a 75 g oral glucose tolerance test (OGTT), or random plasma glucose ≥ 11.1 mmol/L with typical symptoms of hyperglycaemia or hyperglycaemic crisis.

2.4. Animal experiments, tumour induction, and oral glucose tolerance test

10-week old male db/db mice (Jackson Stock #000642, BKS.Cg-Dock7m+/+Leprdb/ J) were obtained from the CUHK Laboratory Animal Services Centre and transferred to the Animal House of the Li Ka Shing Institute of Health Sciences (LKS) based at the PWH. All mice were housed in a temperature-controlled room (22 °C) on a 12-h light-dark cycle with free access to food and water at the PWH.

To examine the cancer-promoting effect of PSMA2 and anti-cancer effect of Exendin-4, we inoculated db/db mice with the same number (2 × 10^6) of CUP-1 cells, psma2-shRNA transfected CUP-1 cells, or psma2-vector transfected CUP-1 cells subcutaneously underneath the nape of the neck (scruff). After inoculation (Day 0), the mice were assigned to receive either a daily intraperitoneal injection of Exendin-4 (30 nM/kg body weight) [31] or PBS for 13 days with 7–10 mice in each group.

On day 3, tumour developed at the scruff of the mice, and the size was measured by calliper (Mitutoyo, Taiwan) twice weekly during the treatment period. Tumour volumes were calculated using the equation V = (a x b x c) / 2, where “a” was the larger dimension and “b” the perpendicular diameter [35]. Bodyweight, food consumption, and random blood glucose were also measured twice weekly during the treatment period. None of the mice developed a tumour larger than 2 x 2 cm^2 to meet the exclusion criteria.

On day 14, an oral glucose tolerance test (OGTT) was performed after overnight fasting for 15 h to examine the anti-diabetic effects of Exendin-4. For OGTT, the mice were gavaged with 20% glucose (1 g/kg) after blood collection at baseline (0 min). All blood samples were
collected from the tail vein at 0, 15, 30, 60, and 120 min for glucose measurements, followed by tumour collection for histological analysis. Mice were sacrificed by inhalation of carbon dioxide provided by the LKS Animal House based at the PWH.

2.5. Plasmid, shRNA, and siRNA transfection

For psma2 overexpression plasmid construction, mouse cDNA encoding psma2 was amplified using the following primers: forward (F) 5'- GACGCCGTTACAGCTTCT-3', reverse (R) 5'- GCAGCTT- TAATCCCCACTGAC-3'. The amplified fragment was sub-cloned into pcDNA3.1 vector between BamH1 (5') and Xhol (3') restriction sites and confirmed by sequencing analysis. The above plasmid DNA fragment was sent to Hanbio (China) for lentiviral expression and packaging.

For psma2 knockdown, shRNA lentivirus particles were purchased from Sigma (Cat. SH0731, USA) and used according to the manufacturer's instructions. Lentivirus overexpression (20 μL of 1 × 10^6 viral titre) or downregulation (200 μL of 1 × 10^5 viral titre) particles were added to the wells for transfection. After 12 h, the medium with lentivirus particles was replaced with fresh medium for incubation for 48h, followed by puromycin selection for at least 14 days. The surviving cells were examined for psma2 expression by RT-PCR and used as cell lines with stable psma2 overexpression or downregulation for molecular and animal studies.

For GLP-1R knockdown, siRNA was purchased from Invitrogen (Cat. 4390771, USA) and used according to the manufacturer's instructions. 15 pmol siRNA particles together with lipofectamine 2000 (Cat. 11668027, Invitrogen, USA) were added to the wells for transfection. After 12 h, the medium was replaced with fresh medium for incubation for 48 h. Western blotting (WB) was performed to validate GLP-1R downregulation.

2.6. MTT and cell proliferation assay

We seeded 1000–2000 cells into each well of 96-well plate for overnight incubation. After treatment based on different experimental design, we added 10 μL MTT Reagent (Sigma-Aldrich, USA) into the cell medium for incubation for 4 h until a purple precipitate was visible. The cell medium was replaced with 100 μL DMSO for 2 h incubation in the dark, followed by absorbance record at 570 nm. 3000 cells of each cell line were seeded in 96-well cell culture plates for overnight incubation. After treatment based on different experimental design, cell proliferation was analysed daily up to 72 h by cell counting using a haemocytometer.

2.7. Histological staining

We used human cervical cancer histological samples from Department of Anatomical and Cellular Pathology CUHK for PSMA2 and GLP-1R immunofluorescence (IF) staining. Mice tumour was collected after treatment and fixed in 4% (v/v) paraformaldehyde overnight and embedded in paraffin. Sections were cut to 4 μm thickness for IF staining of Ki67 and PSMA2.

For IF staining, after rehydration, slides were placed in 0.5% (v/v) triton X for 20 min for permeabilization, followed by 0.01 mol/L sodium citrate buffer (pH 6.0) and heated at ~100 °C for 10 min for antigen retrieval. After blocking nonspecific antibodies, rabbit anti-Ki67, PSMA2, or GLP-1R antibody was applied to the sections overnight at 4 °C. The sections were then washed in PBS/T three times and incubated with fluorescence-conjugated secondary antibodies, Alexa Fluor® goat anti-rabbit 555 at room temperature (RT) for 1 h, followed by counterstaining of the nucleus with DAPI. The images were captured using the Leica Qwin image analysis software (Leica, Germany). Table S1 lists the antibodies used in these experiments.

Images of at least 10 vision fields were captured in each slide and positive signals were quantified using Image J.

2.8. Real-time PCR and immunoblotting

We used Trizol (Invitrogen, USA) to extract total RNA in all cell models, followed by reverse transcription to cDNA (Takara, Japan). cDNA was applied to SYBR-Green Kit (Promega, USA) and then Applied Biosystems 7900HT for quantitative RT-PCR analysis. Mouse primers are shown in table S1.

Total proteins from cells were extracted using ice-cold cell lysis buffer (Cat. #9803, Cell Signalling Technology, USA) supplemented with protease inhibitor (Roche, Switzerland) and Na3VO4 and then adjusted to the same concentration by loading buffer and denatured. After gel electrophoresis, transfer and blocking, membranes were incubated in the primary antibodies at 4 °C overnight. The primary antibodies included PSMA2, GLP-1R, phospho-P65, P65, phospho-IkB, IkB, and GAPDH. HRP-linked anti-rabbit and anti-mouse IgG were used as secondary antibodies. Protein bands were developed by Immobilon Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA, USA). Table S1 lists the antibodies used in these experiments.

2.9. Statistical analysis

In TCGA data analysis, for each type of cancer, we used ANOVA to compare expression profiles between cancerous and normal samples. Statistical significance was defined as an absolute log2 fold change > 0.5 and a p-value < 0.001.

In animal experiments, we calculated the sample size to be 7 in each group (28 in total) based on the mean and standard deviation (SD) (mean±SD) of tumour volume in the Exendin-4 group (500±110 mm^3) and control group (700±120 mm^3) in a pilot study (n = 3 in each group), to achieve 90% power with an alpha (p) value less than 0.05. Mice were randomly assigned to treatment or control group. Treatment and measurements were performed at the same time daily and in a random order to minimise potential confounders. The conduct of experiment, tumour size measurements, and data analysis were performed by different investigators blinded to the treatment group. Mice were excluded if the tumour volume exceeded 2 × 2 cm^2. All data are presented as mean±SD (95% CI) with individual data point shown in histograms. We plotted the data to confirm their normal distribution. We used Student's t-test and two-way ANOVA with Tukey's post hoc test, as appropriate, to examine between-group differences using Prism (GraphPad Prism 7, San Diego, CA, USA) with significance defined as p < 0.05.

In the analysis of human cervical cancer specimens, we included patients who underwent hysterectomy for cervical cancer at the PWH in 2016–2019, who consented to donate their cancer specimens for research. We excluded those with immunodeficiency or active substance abuse and identified patients who met inclusion criteria for T2D and selected control subjects matched by age. We performed a pilot study with 3 samples in each group and calculated a sample size of 9 in each group was required based on the mean±SD of PSMA2 RNA expression in the non-T2D group (1±1.4) and T2D group (3±1.5, fold change) to achieve a power of 0.8 with an alpha (p) value less than 0.05. The experiments and data analysis were conducted with the analyst blinded to the group assignment. We compared PSMA2 and GLP-1R expression between the T2D and non-T2D group and performed correlation analysis in each group. A p-value < 0.05 (2-tailed) was considered as statistically significant.

2.10. Ethics

The human study protocol was approved by the Joint CUHK-New Territories East Cluster Clinical Research Ethics Committees (CREC
Ref. No.: 2018.457). All patients gave written informed consent for research and publication purposes. The animal experimental protocol was approved by the Animal Experimentation Ethics Committee of CUHK (AEEC Ref. No.: 17-089-MIS). All animal procedures were compliant with guidelines on animal use.

2.11. Role of the funding source

The funders had no role in experimental design, data collection, data analyses, interpretation, or manuscript writing. We were not paid to write this article by any company or agency. The corresponding author had full access to all data in this study.

2.12. Results

Increased PSMA2 expression in 12 human cancer types and cervical cancer specimens from patients with T2D, further confirmed in multiple cervical cancer cell lines.

We identified tumour-specific overexpression of PSMA2 in 12 types of cancer from TCGA database, compared with respective normal tissues from the GTEx database. These included breast, cervical, cholangial, colorectal, lymphoid, oesophageal, head and neck, liver, lung, pancreatic, stomach, and thymus cancer (Fig. 2a). Based on the statistically significant increase in PSMA2 expression in cervical cancer, and the emerging role of PSMA2 in both cancer and diabetes [13,14,36], we examined PSMA2 expression in cervical cancer specimens from patients with or without T2D, multiple human and mouse cervical cancer cell lines and non-cancerous cell lines.

Fig. 1 lists the flowchart of participant selection for analysis of PSMA2 expression in cervical cancer specimens. Table 2 lists the clinical characteristics of the selected participants in this study. We retrieved these subjects’ specimens for IF staining and RT-PCR analysis for PSMA2 expression. In Fig. 2b and c, patients with T2D had higher PSMA2 protein expression than those without T2D (T2D: 0.59%, 95% CI: 0.47–0.72; Non-T2D: 0.36%, 95% CI: 0.25–0.46; P = 0.004, t-test) (n = 9 in each group). In Fig. 2d, RT-PCR analysis revealed a 3-fold increase in PSMA2 expression in patients with T2D (T2D: 3.22 (fold change), 95% CI: 1.38–5.05; Non-T2D: 1.00, 95% CI: 0.66–1.34; P = 0.01, t-test).

To test the hypothesis of whether high glucose condition would alter the expression of this potential proto-oncogene, we determined the PSMA2 expression in multiple epithelial cervical cancer cell lines. High glucose (25 mmol/L) increased PSMA2 expression in SiHa (P = 0.04, t-test), HeLa (P = 0.04, t-test), and C33A cells (P = 0.04, t-test), but not in non-cancerous mouse fibroblast and human embryonic kidney cells (Fig. 2e). In CUP-1 cells, exposure to high glucose also upregulated psma2 expression in a glucose-dose-dependent manner (normal glucose (NG) vs low glucose (LG): ~1.5 folds, P = 0.008, t-test; HG vs NG: ~1.5 folds, P = 0.04, t-test) (Fig. 2f).

2. Psma2-O/E and -shRNA increased and decreased cell proliferation and tumour volume respectively under high glucose environment

We treated CUP-1 cells with psma2-O/E or -shRNA under normal or high glucose condition followed by cell viability and proliferation assay. High glucose promoted cell proliferation in CUP-1 cells (P = 0.001, t-test). Enforced psma2-O/E transfection also promoted CUP-1 cell proliferation under normal (P = 0.002, t-test) and high glucose conditions (P = 0.005, t-test) (Fig. 3a and b). Consistent with the above results, psma2-shRNA reduced cell viability and proliferation in normal and in high glucose conditions in vitro (Fig. 3c and d). The RNA and protein expression of PSMA2 in the above conditions was confirmed (Fig. 3e-h).

To determine the role of psma2 in the hyperglycaemic background in vivo, we inoculated CUP-1 cells, or psma2-shRNA transfected CUP-1 cells into db/db mice to induce tumour development. Mice inoculated with psma2-shRNA-CUP-1 cells had smaller tumour volume, compared with vector control group (P = 0.002, ANOVA test) (Fig. 3i and j). Tumour with psma2-shRNA-CUP-1 cells had decreased Ki67 expression, indicative of reduced tumour proliferation in vivo (PSMA2-shRNA vehicle: 0.26%, 95% CI: 0.09–0.42; vector control: 0.46%, 95% CI: 0.32–0.60; P = 0.028, t-test) (Fig. 3k and l). Downregulation of psma2 did not alter blood glucose level in vivo, suggesting that the anti-cancer effect was not glucose-mediated (SFig. 2a–c).

**Fig. 1.** Flowchart of participant selection for analysis of cervical cancer.
3 Exendin-4 reduced PSMA2 expression, cell proliferation, and tumour volume in vitro and in vivo

We treated human and mouse (CUP-1) cervical cancer cell lines with Exendin-4 to examine PSMA2 expression. We treated psma2-O/E-CUP-1 cells and psma2-shRNA-CUP-1 cells with Exendin-4 under normal or high glucose condition for cell viability and proliferation assay. Under high glucose condition, Exendin-4 (50 mmol/L) decreased PSMA2 expression in CUP-1 cells by 3-fold \((P = 0.01, \text{t-test})\) and in SiHa \((P = 0.01, \text{t-test})\), HeLa \((P < 0.001, \text{t-test})\), and C33A \((P = 0.04, \text{t-test})\) cells (Fig. 4h). Exendin-4 did not alter psma2 expression and cell proliferation in psma2-shRNA-CUP-1 cells (Fig. 4b–d). In psma2-O/E-CUP-1 cells, Exendin-4 reduced psma2 expression by 60% \((P = 0.003, \text{t-test})\) and cell viability and proliferation \((P < 0.001, \text{ANOVA})\) under high glucose condition (Fig. 4e–g).

We inoculated CUP-1 cells into db/db mice to induce tumour development with or without Exendin-4 treatment. Consistent with the above in vitro findings, Exendin-4 treatment reduced the tumour volume \((P < 0.001, \text{ANOVA})\) test), starting from day 7 (Exendin-4 vs vehicle control: 513.6 (95% CI: 408.4–618.7) vs 749.9 (95% CI: 273.3–1216.4)).
**Fig. 3.** Psma2-O/E and -shRNA increased and decreased cell proliferation and tumour volume respectively under high glucose environment Cell viability (a) and proliferation (b) were measured in CUP-1 cells with and without psma2-O/E in normal or high glucose medium by MTT and cell counting. The upregulation of the RNA and protein expression of psma2 was confirmed after enforced overexpression by RT-PCR and WB (e, f). Cell viability (c) and proliferation (d) were measured in CUP-1 cells with and without psma2-shRNA in normal or high glucose medium by MTT and WB. Downregulation of the RNA expression of psma2 was confirmed after psma2-shRNA transfection by RT-PCR and WB (g, h). (e-f) Tumour volume was measured twice weekly after inoculation of CUP-1 cells with psma2-shRNA or vector into db/db mice (N = 7 in each group) (l, j). Cell proliferation marker Ki67 (k, l) was measured in the tumour of the above diabetes/cancer mice (red: Ki67, blue: DAPI, magnification: ×200. The white scale bar represents 50 μm). Data are presented as mean±SD with individual data points in histograms. * p < 0.05, ** p < 0.01, *** p < 0.001. (For interpretation of the references to color in this figure legend, reader can refer to the web version of this article.)
639.4–860.4 mm², \( P = 0.003, \) t-test) (Fig. 4i and j). Exendin-4 decreased Ki67 (Exendin-4: 0.27%, 95% CI: 0.07–0.47; vehicle control: 0.47%, 95% CI: 0.35–0.59; \( P = 0.04, \) t-test) (Fig. 4k and l) and PSMA2 expression (Exendin-4: 0.39%, 95% CI: 0.23–0.55; vehicle control: 0.61%, 95% CI: 0.44–0.78; \( P = 0.03, \) t-test) in tumours, compared with the vehicle-treated group (Fig. 4m and n).

In human cervical cancer specimen, GLP-1R expression was increased and positively correlated with PSMA2 expression in patients with T2D, supplemented by experimental evidence in multiple cervical cancer systems.

To understand why Exendin-4 exerted the aforementioned effects, we first examined the RNA expression of GLP-1R in 13 types of cancer from TCGA database. There was no expression difference between tumour tissues and respective normal tissues, although diabetes status in these patients was unknown (Fig. 5a). We then analysed the protein and RNA expression of GLP-1R in human cervical cancer specimens and multiple cervical cancer cell lines. We found a 2-fold increase in GLP-1R protein expression (T2D: 0.39%, 95% CI: 0.30–0.48; Non-T2D: 0.21%, 95% CI: 0.13–0.30; \( P = 0.004, \) t-test) (Fig. 5b and c) and a 5-fold increase in GLP-1R RNA expression in cervical cancer specimens from patients with T2D, compared with those without T2D (T2D: 5.49 (fold change), 95% CI: 3.00–7.98; Non-T2D: 1.00, 95% CI: 0.5–1.5; \( P = 0.003, \) t-test) (Fig. 5d). We performed correlation analysis between PSMA2 and GLP-1R expression in the T2D and non-T2D group separately. There was positive correlation in the T2D (\( r = 0.68, 95\% \text{ CI: } 0.02–0.92, P = 0.046, \) correlation test) but not in the non-T2D group (\( r = 0.29, 95\% \text{ CI: } 0.47–0.80, P = 0.46, \) correlation test) (Fig. 5e and f).

High glucose increased RNA and protein expression of GLP-1R in human and mouse cervical cancer cell lines (Fig. 5g–h, i–m). In CUP-1 cells, GLP-1R expression was increased in a glucose-dose-dependent manner (NG vs LG: ~3 folds, \( P = 0.001, \) t-test; HG vs NG: ~3 folds, \( P = 0.007, \) t-test) (Fig. 5h). Upon knockdown of GLP-1R, there was correspondingly reduced expression of PSMA2 under normal and high glucose conditions (Fig. 5m–o).

High glucose activated NF-κB signalling pathway but attenuated by Exendin-4 in CUP-1 cells.

We treated CUP-1 cells with or without Exendin-4 under normal or high glucose condition to evaluate the protein expression of psma2 and NF-κB signalling inflammatory markers phospho-p65 and phospho-IκB. High glucose increased psma2 protein expression (\( P = 0.02, \) t-test), which was attenuated by Exendin-4 (\( P = 0.003, \) t-test) (Fig. 6a and b). High glucose increased protein expression of phospho-p65 (\( P = 0.04, \) t-test) and phospho-IκB (\( P = 0.003, \) t-test), which were attenuated by Exendin-4 (Fig. 6c and d).

3. Discussion

In this translational study, we have used human and experimental studies to test the hypothesis regarding the roles of PSMA2 and GLP1-RA in cervical cancer with data summarised in Table 1. We discovered, PSMA2 and GLP-1R expression were increased and positively correlated in cervical cancer specimens from patients with T2D. Exendin-4 attenuated PSMA2 expression and tumour growth in vivo and in vitro. In TCGA database, PSMA2 was over-expressed in 12 human cancer types. Experimentally, high glucose increased PSMA2 expression in multiple human and mouse epithelial cervical cancer cell lines (CUP-1), the latter being glucose-dependent, but not in non-cancerous cells. In the CUP-1 cells, psma2-O/E and psma2-shRNA increased and decreased cell proliferation, respectively. In vivo, psma2-shRNA attenuated tumour growth and cell proliferation. In vitro, high glucose upregulated psma2 expression and cell proliferation in CUP-1 cells, which were exacerbated with psma2-O/E but attenuated by Exendin-4. The latter also attenuated tumour growth, cell proliferation and PSMA2 expression in vivo. There was no difference in GLP-1R expression in 12 cancer types in TCGA database, albeit with unknown glycaemic status. GLP-1R expression was increased...
Fig. 4. Exendin-4 reduced PSMA2 expression, cell proliferation, and tumour volume in vitro and in vivo. (a) The RNA expression of psma2 was measured in CUP-1 cells after treatment with Exendin-4 at the concentration of 0, 5, 20, and 50 nmol/L for 48 h in normal or high glucose medium. (b-d) The RNA expression of psma2, cell viability, and proliferation were examined in psma2-shRNA-CUP-1 cells with or without Exendin-4 treatment in normal or high glucose medium. (e-g) The RNA expression of psma2, cell viability, and proliferation were examined in psma2-O/E-CUP-1 cells with or without Exendin-4 treatment in normal or high glucose medium. (h) The RNA expression of psma2 was examined in SiHa, HeLa, and C33A human cervical cancer cell lines with or without Exendin-4 treatment in normal or high glucose medium. (i-j) Tumour volume was measured twice weekly after inoculation of CUP-1 cells with treatment of Exendin-4 (30 nmol/kg) or vehicle (PBS) (N = 7 in each group). Cell proliferation marker Ki67 (k-l) (red: Ki67, blue: DAPI, magnification: × 200). The white scale bar represents 50 μm. PSMA2 expression (m-n) were measured in the tumour of above diabetes/cancer mice (red: PSMA2, blue: DAPI, magnification: × 400). The white scale bar represents 25 μm. Data are presented as mean±SD with individual data points in histograms. * p < 0.05, ** p < 0.01, *** p < 0.001. (For interpretation of the references to color in this figure legend, reader can refer to the web version of this article.)
and positively correlated with PSMA2 in cervical cancer specimens from patients with T2D, which were further validated by GLP-1R knockdown in CUP-1 cells. GLP-1R expression was increased in multiple human cervical cancer cell lines under high glucose condition and in CUP-1 cells in a glucose-dose-dependent manner. High glucose upregulated protein expression of psma2, p-P65, and p-κB but attenuated by Exendin-4. Taken together, our data support the promoting effect of high glucose on GLP-1R and PSMA2 expression in cervical cancer, which can be attenuated by Exendin-4.

In experimental studies of diabetes, high glucose impaired the ubiquitin-proteasome system function to cause abnormal cardiovascular-renal function and amyloid precipitation in islets [36]. High glucose activated the hexosamine-polyol-dicarbonyl methylglyoxal (MGO) pathways accompanied by decreased proteasome activity in diabetic kidney disease models [37]. On the other hand, MG132, a proteasome inhibitor, attenuated diabetic nephropathy by enhancing renal antioxidative capacity and histone degradation [38–40]. Increased proteasome expression was implicated in atherosclerosis [41], while insulin deficiency activated proteasome activity and caused cardiac muscle dysfunction [42]. However, these experimental results were not always consistent. In human studies, both decreased and increased proteasome expression had been reported in specimens from patients with T2D and cardiovascular disease [43]. In contrast, the upregulation of the ubiquitin-proteasome system had been consistently reported in carcinogenesis [44]. This was supported by the use of proteasome inhibitors as first-line adjunctive drugs in addition to conventional chemotherapy in patients with multiple myeloma to maximize efficacy and minimize treatment resistance [45].

Proteasome alpha subunit has seven isoforms encoded by seven genes PSMA1-7. In TCGA database, we noted increased PSMA2 expression in 12 human cancer types, including cervical epithelial cancer. In vitro, we confirmed high glucose increased PSMA2 expression and cell proliferation in cervical and breast cancer cell lines attenuated by Exendin-4 (Sfig. 1). This effect was corroborated by increased tumour growth in the diabetes/cancer model. The proto-oncogenic role of psma2 was confirmed by transfection studies where psma2-O/E enhanced, and psma2-shRNA reduced cancer growth. In vivo, psma2-shRNA did not alter blood glucose level, suggesting that this effect was independent of glucose-lowering effect (Sfig. 2). These experimental results were corroborated by increased expression of PSMA2 in cervical cancer specimens from patients with T2D. These original findings suggested that dysregulation of PSMA2 might underlie the high risk of cancer in T2D. The glucose-dependent upregulation of PSMA2 in breast cancer cells (Sfig. 1a) and its increased expression in multiple cancer types in TCGA database, along with the genetic associations of PSMA2 SNPs with various cancer types [14,15] suggest that the proto-oncogenic role of PSMA2 might apply to other cancer cell types.

There are few studies which systematically examined the effects of hyperglycaemia on cancer and the therapeutic effects of glucose lowering drugs on cancer. The mechanism of Exendin-4 on tumour attenuation was multifactorial. Previous evidence indicated that Exendin-4 attenuated prostate tumour growth by inhibiting extracellular phosphorylation in signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) pathway and inhibition of NF-κB activation [23,46,47]. In our study, Exendin-4 reduced high-glucose-upregulated PSMA2 expression, but not in normal glucose condition in cervical cancer cells. Different cancer types might exhibit different behaviours with different dominant pathologies. Unlike prostate cancer, cervical cancer was mainly induced by HPV infection, and the inflammation might be exaggerated by hyperglycaemia [48]. The anti-inflammatory effect of Exendin-4 has been well reported [27,49]. PSMA was involved in proinflammatory pathways and whether the anti-cancer effect of Exendin-4 through PSMA reduction was mediated by anti-inflammation required further elucidation. Given the cross-talk between hyperglycaemia and inflammation [50], our study provided new insights regarding the potential of using Exendin-4 to treat cancer in patients with T2D.

The effect of hyperglycaemia on GLP-1R expression in cancer and non-cancer tissues might be different. Chronic hyperglycaemia decreased GLP-1R expression in pancreatic beta cells in diabetes, which might contribute towards the impaired incretin and insulin secretion [51]. In patients with obesity, decreased GLP-1R expression had been reported in vascular endothelial cells [52]. By contrast, increased expression of GLP-1R expression had been reported in various types of human tumour, including endocrine tumours and lung cancer [53,54]. According to the Warburg’s hypothesis, cancer cells exhibit high rates of glycolysis with lactic acid production, which might require increased glucose uptake [55,56]. Taken together, we hypothesized that in cancer cells, hyperglycaemia might increase GLP-1R expression to promote glucose uptake to fuel cell growth.

In support of this hypothesis, we demonstrated that high glucose increased GLP-1R expression in human and mouse epithelial cervical cancer cell lines. These findings were corroborated by increased expression of PSMA2 and GLP-1R and their positive correlations in cervical cancer specimens only from patients with T2D. The cross-talk between GLP-1R and PSMA2 pathways in carcinogenesis was
Fig. 5. In human cervical cancer specimen, GLP-1R expression was increased and positively correlated with PSMA2 expression in patients with T2D, supplemented by experimental evidence in multiple cervical cancer systems. GLP-1R expression was examined in TCGA database (a). The protein (b, c) (red: GLP-1R, blue: DAPI, magnification: × 400. The white scale bar represents 25 μm) and RNA expression (d) of GLP-1R was examined in cervical cancer specimens from patients with and without T2D. (e-f) Correlation analysis was performed between GLP-1R and PSMA2 expression in cervical cancer specimens from patients with and without T2D. The RNA expression of GLP-1R was examined in human cervical cancer cell lines (g) and CUP-1 cells (h). GLP-1R protein expression was examined in human cervical cancer cell lines under normal and high glucose medium (i-l). GLP-1R and PSMA2 protein expression in CUP-1 cells with or without GLP-1R siRNA transfection (m-o). Data are presented as mean ± SD with individual data points in histograms. * p < 0.05, ** p < 0.01, *** p < 0.001. (For interpretation of the references to color in this figure legend, reader can refer to the web version of this article.)
plausible. Proteasome inhibitor attenuated widespread inflammation by inhibiting the NF-κB pathway [57]. Proteasome could degrade IκB and liberated the inflammatory signal of P65 to activate subsequent nuclear transcription of inflammatory genes [58]. Other researchers had reported the anti-inflammatory effects of Exendin-4 on macrophage migration in vitro as well as on breast cancer growth [59,60]. In our study, Exendin-4 attenuated phosphorylation of the P65 and IκB in the NF-κB pathway, but the molecular mechanism underlying this inhibitory effect required further elucidation.

There are limitations in this study. More experiments are needed to elucidate the mechanism underlying the inhibitory effects of Exendin-4 on PSMA2 expression. The mechanisms underlying the activation of proteasome in cancer development is complex, including but not limited to chaperone protein overexpression, catalytic subunits downregulation, upstream enzymes and transcription factor activation [61]. The IKK inhibitor, a key blocker of the NF-κB pathway, can be used to determine whether the cancer-promoting effects of high glucose through psma2 expression is mediated by the NF-κB pathway activation, which is known to promote inflammation and tumour growth [62]. We are currently designing a series of experiments to explore the molecular mechanisms underlying the cross-talk between PSMA2 and GLP-1R, which is beyond the scope of this study.

Fig. 5. Continued.

Fig. 6. High glucose activated NF-κB signalling pathway but attenuated by Exendin-4 in CUP-1 cells. (a-d) Quantitative data was calculated in each group. Data are presented as mean±SD with individual data points in histograms. * p < 0.05, ** p < 0.01, *** p < 0.001.
Table 1
Outcome measures in various experimental models.

| Human cervical cancer | Mouse epithelial cervical cancer (CUP-1) | Human cervical cancer cell lines (SiHa, HeLa, C33A) | CUP-1-induced tumour model in db/db mice |
|-----------------------|------------------------------------------|-----------------------------------------------------|------------------------------------------|
| 1. TCGA database:     | HG: ↑ PSMA2 RNA expression in a glucose-dose-dependent manner (Fig. 2f) | HG: ↑ PSMA2 RNA expression (Fig. 2e) | 1. PSMA2-shRNA: ↓ tumour volume (Fig. 3c-i) |
| 2. Human cervical cancer samples from PWH-CULIC: | HG: ↑ cell viability and proliferation (Fig. 3a, b) | HG: ↑ PSMA2 expression (Fig. 2e) | 2. PSMA2-shRNA: ↓ Ki67 expression in tumour (Fig. 3k, l) |
| 3. ↑ PSMA2 protein expression in T2D (Fig. 1b, c) | PSMA2-O/E: ↑ cell viability and proliferation (Fig. 3a, b) | PSMA2-shRNA: ↓ cell viability and proliferation (Fig. 3c, d) | Vector control: 0.46% (0.32-0.60) |
| Non-T2D: 0.36% (0.25-0.46) | T2D: 0.59% (0.47-0.72) (fold change) | PSMA2-O/E and PSMA2-shRNA validation (Fig. 3e-h) | PSMA2-shRNA vehicle: 0.26% (0.09-0.42) |
| 4. ↑ PSMA2 RNA expression in T2D (Fig. 2d) | Exe-4: ↓ PSMA2 RNA (Fig. 4a) and protein (Fig. 6a) expression under HG | Exe-4: ↓ PSMA2 RNA expression under HG (Fig. 4h) | 3. Exe-4: ↓ tumour volume (Fig. 4i, j) |
| Non-T2D: 1.00 (0.66-1.34) | T2D: 1.22 (1.38-1.05) (fold change) | | 4. Exe-4: ↓ Ki67 protein expression in tumour (Fig. 4k, l) |
| 5. ↑ GLP-1R protein expression in T2D (Fig. 5b, c) | Exe-4: ↓ PSMA2 RNA expression, ↓ cell viability and proliferation under HG in PSMA2-O/E cells (Fig. 4e-g) | Exe-4: (-) PSMA2 RNA expression, (-) cell viability and proliferation in PSMA2-shRNA cells (Fig. 4b-d) | |
| Non-T2D: 0.21% (0.13-0.30) | T2D: 0.39% (0.30-0.48) (fold change) | HG: ↑ GLP-1R RNA expression in a glucose-dose-dependent manner (Fig. 5e) | HG: ↑ GLP-1R RNA and protein expression (Fig. 5g, i) |
| 6. ↑ GLP-1R RNA expression in T2D (Fig. 5d) | Exe-4: ↑ GLP-1R protein expression (Fig. 5i) | Vehicle control: 0.47% (0.35-0.59) | Exe-4: 0.27% (0.07-0.47) |
| Non-T2D: 1.00 (0.5-1.5) | T2D: 5.49 (3.00-7.98) (fold change) | GLP-1R siRNA: ↓ PSMA2 protein expression in (Fig. 5m-o) | Vehicle control: 0.61% (0.44-0.78) |
| 7. (-) correlation in RNA expression between PSMA2 and GLP-1R in T2D, but not in non-T2D. (Fig. 5e, f) | HG: ↑ p-P65, p-κB protein expression, but ↓ by Exe-4 (Fig. 6a-d) | Exe-4: 0.39% (0.23-0.55) | |

↑: increase; ↓: decrease; (-): no change; T2D: type 2 diabetes; Exe-4: exendin-4; TCGA: the Cancer Genome Atlas Program; HG: high glucose; O/E: overexpression. Data are presented as point estimate and 95% confidence interval (CI).
paper. In our in vivo studies, we had only measured tumour volume. Although it is preferable to measure both tumour weight and tumour volume, the latter had been reported as the only measurement by other workers [63]. The case-control clinical study was subject to selection bias since only samples from Chinese women were included. We did not adjust for confounding factors such as treatment or other risk factors. Further studies in other ethnic groups will be required to validate these observations. However, the increased expression of PSM2A2 and GLP-1R and their positive correlation in patients with T2D concorded with the results from our experimental studies.

In sum, our consistent results allow us to conclude that high glucose increased PSM2A2 expression and promoted tumour growth, which could be attenuated by Exendin-4. The latter effects might be mediated by reducing psm2a2 and NF-κB pathway activity. Since proteasome inhibitors and GLP-1 mimetics are in clinical use, our data have strong translational potential, especially in patients with T2D and cancer, which co-expressed PSM2A2 and GLP-1R. In these patients, the anti-cancer effect of Exendin-4 should be explored in clinical trials.

**Contributors**

Principal design of the study, conception of study, writing of manuscript: J.C, D.M, VWYL. Design of experiments and interpretation of data: D.M, J.C, P.K.S.C, Histopathological analysis and interpretation: D.M, Experimental procedures: D.M, X. M, H.M.L, Human sample process: D.M, C.C.W, J.K, J.J.X., Bioinformatic analysis: M.S., Data verification: D.M and Y.H.

All authors have read and approved the final version of the manuscript with access to the raw data.

**Data sharing statement**

All datasets generated or analysed in the current study are available from the corresponding author on reasonable request.

**Declaration of Competing Interest**

JCNC reported receiving research grants and/or honoraria for consultancy or giving lectures from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Pfizer, and Sanofi. EC reported receiving grants from Lee Powder and Sanofi. VWYL received a University-Industry Collaboration Program (UIM/329; from the Innovation and Technology Fund, Hong Kong government, and Lee’s Pharmaceutical [Hong Kong Limited] in 2018–2020) and served as a scientific consultant for Novartis Pharmaceutical (Hong Kong) Limited (Oct 2015–Oct 2016).

**Acknowledgements**

This project was supported by the CUHK Postdoctoral Fellowship Scheme. CUHK Direct Grant and CUHK Diabetes Research and Education Fund of the Department of Medicine and Therapeutics, Faculty of Medicine, CUHK.

VWYL is funded by the General Research Fund (#17121616, #14168517), Research Impact Fund (#R4017-18) from Research Grant Council, Hong Kong; the Health and Medical Research Fund (HMRF #15160691, the Health and Medical Research Fund, the Food and Health Bureau, the Government of the Hong Kong SAR), University-Industry Collaboration Program (UIM/329; Innovation and Technology Fund, Hong Kong government), and the Hong Kong Cancer Fund.

**Supplementary materials**

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ebiom.2021.103242.

**References**

[1] Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364(9):829–41.
[2] Yang X, Lee HM, Chan JC. Drug-subphenotype interactions for cancer in type 2 diabetes mellitus. Nat Rev Endocrinol 2015;11(6):372–9.
[3] Yang X, Ko GT, So WY, Ma RC, Yu LW, Kong AP, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 2010;59(5):1254–60.
[4] Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2(5):342–50.
[5] Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860–7.
[6] Chen S, Tao M, Zhao L, Zhang X. The association between diabetes/hyperglycemia and the prognosis of cervical cancer patients: a systematic review and meta-analysis. Medicine 2017;96(40):157–65.
[7] Crawford LJ, Walker B, Irvine AE. Proteasome inhibitors in cancer therapy. J Cell Commun Signal 2011;5(2):101–10.
[8] Meng X, Zhong J, Liu S, Murray M, Gonzalez-Angulo AM. A new hypothesis for the cancer mechanism. Cancer Metastasis Rev 2012;31(1-2):247–68.
[9] Jung H. Regulation of protein degradation by proteasomes in cancer. J Cancer Prev 2018;23(4):153–61.
[10] Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003;29:3–9.
[11] Arlt A, Bauer I, Schafmayer C, Kropf J, Muerkoster SS, Brosch M, et al. Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene 2009;28(45):3983–96.
[12] Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61(7):3071–6.
[13] Petrocca F, Altshuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ, et al. A genomewide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell 2013;24(2):182–96.
[14] Sjbolm T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314(5797):268–74.
[15] Comes AV. Genetics of proteasome diseases. Scientia 2013;2013:629–49.
[16] Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012;120(5):947–59.
[17] Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60(4):470–512.
[18] Shiyanbola DS, Royle P, Czar C, Sharma P, Waugh N, Snash A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;2011(10):CD007468.
[19] Dicker D. DPP-4 Inhibitors. Impact on glycemic control and cardiovascular risk factors. 2011;34:276–8.
[20] Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, et al. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes 2014;63(11):3891–905.

---

**Table 2**

Clinical characteristics of patients with cervical cancer selected for analysis.

| Case No. | Age (Y) | Ethnicity | Date of Operation (dd/mm/year) | T2D | HbA1c (%) |
|----------|---------|-----------|-------------------------------|-----|-----------|
| C1208    | 58      | Chinese   | 22/12/2017                    | Yes | 11.9      |
| C1191    | 84      | Chinese   | 04/08/2017                    | Yes | 6.8       |
| C1180    | 57      | Chinese   | 19/04/2017                    | Yes | 7.6       |
| C1183    | 57      | Chinese   | 15/09/2014                    | Yes | 6.5       |
| C1177    | 57      | Chinese   | 19/04/2017                    | Yes | 7.6       |
| C1147    | 41      | Chinese   | 18/01/2016                    | Yes | 7.5       |
| C1213    | 40      | Chinese   | 18/01/2019                    | Yes | 6.9       |
| C1234    | 54      | Chinese   | 29/04/2019                    | Yes | 9.4       |
| C1219    | 51      | Chinese   | 09/02/2018                    | Yes | Nil*      |
| C1195    | 84      | Chinese   | 17/08/2017                    | No  | 5.5       |
| C1203    | 37      | Chinese   | 22/11/2017                    | No  | 5.1       |
| C1210    | 51      | Chinese   | 05/01/2018                    | No  | Nil       |
| C1220    | 59      | Chinese   | 22/03/2018                    | No  | Nil       |
| C1228    | 61      | Chinese   | 18/05/2018                    | No  | Nil       |
| C1229    | 56      | Chinese   | 08/06/2018                    | No  | Nil       |
| C1157    | 47      | Chinese   | 22/08/2016                    | No  | Nil       |
| C1185    | 70      | Chinese   | 17/05/2017                    | No  | Nil       |
| C1182    | 38      | Chinese   | 24/04/2017                    | No  | Nil       |

*documented physician-diagnosed T2D.
Huang W, Shao Y, Yu Y, Huang W, Feng G, Li J. Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation. Prostate 2020;80(5):367–75.

Zhou HJ, Jiang X, Hu LJ, Yang L, Deng LD, Wang YP, et al. Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells. J Mol Endocrinol 2020;64(2):103–13.

Iwaya C, Nomiyama T, Komatsu S, Kawanami T, Tsutsumi Y, Hamaguchi Y, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-κB activation. Endocrinology 2017;158(12):4218–32.

Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine 2019;6(6):157–65.

Nomiyama T, Yanase T. GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control. Expert Rev Endocrinol Metab 2016;11(4):357–64.

Insueta DB, Carvalho VF. Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds. Eur J Pharmacol 2017;812:64–72.

He L, Wong CK, Cheung KK, Yao HC, Fu A, Zhao HL, et al. Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes. J Diabetes Investig 2013;4(3):82–92.

Kong AP, Chan JC. Cancer risk in type 2 diabetes. Curr Diab Rep 2012;12(4):325–8.

Kong AP, Yang X, So YW, Luk A, Ma RC, Ozaki R, et al. Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-cause cancer risk in patients with type 2 diabetes. BMC Med 2014;12:76–86.

He L, Law PT, Boon SS, Zhang C, Ho WC, Banks L, et al. Increased growth of a newly established mouse epithelial cell line transformed with HPV-16 E7 in diabetic mice. PLoS One 2016;11(10):1–11.

He L, Law PTY, Wong CW, Chan JCN, Chan PKS. Exendin-4 exhibits enhanced anti-inflammatory effects in diabetic mice. Sci Rep 2017;7(1):339.

Chondrogianni N, Voutetakis K, Kapetanou M, Delitsikou V, Papaevgeniou N, et al. Proteasome activation: an innovative promising approach for cancer therapy. Targeted Ther 2017;2(1):17023.